Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival

OncoImmunology

Volumn 4, Issue 2, 2015, Pages 1-7

  Ferns, Debbie M ^a   Kema, Ido P ^b   Buist, Marrije R ^c   Nijman, Hans W ^b   Kenter, Gemma G ^a,c   Jordanova, Ekaterina S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cervical cancer; IDO; Kyn Trp ratio; Kynurenine; Tryptophan

Indexed keywords

3 HYDROXYKYNURENINE; AMINO ACID; CISPLATIN; IMMUNOMODULATING AGENT; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; TRYPTOPHAN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); DISEASE SPECIFIC SURVIVAL; FOLLOW UP; HUMAN; LIQUID CHROMATOGRAPHY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; METABOLIC ACTIVITY ASSAY; MIDDLE AGED; POSITIVE ION ELECTROSPRAY; PROGNOSTIC ASSESSMENT; RADICAL HYSTERECTOMY; REVERSED PHASE LIQUID CHROMATOGRAPHY; SOLID PHASE EXTRACTION; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TANDEM MASS SPECTROMETRY; UTERINE CERVIX CANCER;

EID: 84954094214     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.981457     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC cancerbase No. 11. Lyon, France: international agency for research on cancer.; 2013 [April 8, 2014]; Available from: http://globocan.iarc.fr
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
4. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74.
6. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013 Mar;34(3):137-43.
7. Prendergast GC, Smith C, Thomas S, Mandik-Nayak L. Laury-Kleintop L, Metz R, Muller AJ. Indoleamine 2, 3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother. 2014 Jul; 63(7):721-35.
8. de Jong RA, Nijman HW, Boezen HM, Volmer M, Ten Hoor KA, Krijnen J, van der Zee AG, Hollema H, Kema IP. Serum Tryptophan and Kynurenine Concentrations as Parameters for Indoleamine 2, 3-Dioxygenase Activity in Patients With Endometrial,Ovarian, and Vulvar Cancer. Int J Gynecol Cancer 2011; 21:1320-7.
9. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoural immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 10:1269-74.
10. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, Margreiter R, Ko€nigsrainer A, Fuchs D, Amberger A. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumour-infiltrating T cells. Clin Cancer Res 2006; 12:1144-51.
11. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991; 5:2516-22.
12. Corm S, Berthon C, Imbenotte M, Biggio V, Lhermitte M, Dupont C, Briche I, Quesnel B. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients’ sera by HPLC and is inducible by IFN-y. Leukemia Res 2009; 33:490-4.
13. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008; 27:3889-900.
14. Kolodziej LR, Paleolog EM, Williams RO. Kynurenine metabolism in health and disease. Amino Acids 2011; 41:1173-83.
15. Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR, Soliman HH. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunol 2013; 3: e23428.
16. Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, Nakamura Y, Inui N, Nakamura H, Chida K. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 2010; 67:361-5.
17. Chuang SC, Fanidi A, Ueland PM, Relton C, Midttun O, Vollset SE, Gunter MJ, Seckl MJ, Travis RC, Wareham N, Trichopoulou A, Lagiou P, Trichopoulos D, Peeters PH, Bas Bueno-de-Mesquita H, Boeing H, Wientzek A, Kuehn T, Kaaks R, Tumino R, Agnoli C, Palli D, Naccarati A, Aicua EA, Sanchez MJ, Quirós JR, Chirlaque MD, Agudo A, Johansson M, Grankvist K, Boutron-Ruault MC, Clavel-Chapelon F, Fagher- azzi G, Weiderpass E, Riboli E, Brennan PJ, Vineis P, Johansson M. Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2014; 23:461-8.
18. Sperner-Unterweger B, Neurauter G, Klieber M, Kurz K, Meraner V, Zeimet A, Fuchs D. Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers. Immunobiol 2011; 216:296-301.
19. Yoshikawa T, Hara T, Tsurumi H, Goto N, Hoshi M, Kitagawa J, Kanemura N, Kasahara S, Ito H, Takemura M, Saito K, Seishima M, Takami T, Moriwaki H. Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol 2010; 84:304-9.
20. Muller AJ, DuHadaway JB, Donover PS, Sutanto- Ward E, Prendergast GC. Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005; 11:312-9.
21. Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA 3rd, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2, 3 dioxygenase. Proc Natl Acad Sci USA. 2008; 105:17073-8.
22. Muller AJ, DuHadaway JB, Chang MY, Ramalingam A, Sutanto-Ward E, Boulden J, Soler AP, Mandik- Nayak L, Gilmour SK, Prendergast GC. Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother. 2010; 59:1655-63.
23. Yu J, Sun J, Wang S, Li H, Cao S, Cong Y, Liu J, Ren X. Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis. Clin Dev Immunol 2011;AI469135.
24. Chung DJ, Rossi M, Romano E, Ghith J, Yuan J, Munn DH, Young JW. Indoleamine 2,3-dioxygenaseexpressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009; 114:555-63.
25. Jurgens B, Hainz U, Fuchs D, Felzmann T, Heitger A. Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood 2009; 114:3235-43.
26. Inaba T, Ino K, Kajiyama H, Shibata K, Yamamoto E, Kondo S, Umezu T, Nawa A, Takikawa O, Kikkawa F. Indoleamine 2, 3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecol Oncol 2010; 117:423-8.
27. Sato N, Saga Y, Mizukami H, Wang D, Takahashi S, Nonaka H, Fujiwara H, Takei Y, Machida S, Takikawa O, Ozawa K, Suzuki M. Downregulation of indole-amine-2,3-dioxygenase in cervical cancer cells suppresses tumour growth by promoting natural killer cell accumulation. Oncol Rep 2012; 28:1574-8.
28. Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O, Saito S. Expression of indoleamine 2, 3-dioxygenase and the recruitment ofFoxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 2007; 98:874-81.
29. Kobayashi A, Weinberg V, Darragh T, Smith-McCune K. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol 2008; 1:412-20.
30. Fotopoulou C, Sehouli J, Pschowski R, von Haehling S, Domanska G, Braicu El, Fusch G, Reinke P, Sche- fold JC. Systemic changes of tryptophan catabolites via the indoleamine-2,3-dioxygenase pathway in primary cervical cancer. Anticancer Res 2011; 31:2629-35.
31. Li J, Cheng H, Zhang P, Dong Z, Tong HL, Han JD, Guo F, Tian YP. Prognostic value of combined serum biomarkers in predicting outcomes in cervical cancer patients. Clin Chim Acta. 2013 Sep 23; 424:292-7.
32. Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 2007; 214:8-14.
33. Pantouris G, Mowat CG. Antitumour agents as inhibitors of tryptophan 2, 3-dioxygenase. Biochem Biophys Res Commun 2014; 443:28-31.
34. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005; 22:633-42.
35. Inaba T, Ino K, Kajiyama H, Yamamoto E, Shibata K, Nawa A, Nagasaka T, Akimoto H, Takikawa O, Kik- kawa F. Role ofthe immunosuppressive enzyme indole- amine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 2009; 115:185-92.
36. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O, Kikkawa F. Inverse correlation between tumoural indo- leamine 2,3-dioxygenase expression and tumour-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 2008; 14:2310-7.
37. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 2002; 196:459-68.
38. Ko HJ, Lee JM, Kim YJ, Kim YS, Lee KA, Kang CY. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J Immunol 2009; 182:1818-28.
39. Li R, Wei F, Yu J. IDO inhibits T-cell function through suppressing Vav1 expression and activation. Cancer Biol Ther 2009; 8:1402-8.
40. Sun J, Yu J, Li H, Yang L, Wei F, Yu W, Liu J, Ren X. Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells. J Exp Cliun CancRes 2011;30:82-92.
41. Smith C, Chang MY, Parker KH, Beury DW, DuHad- away JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller AJ. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2012 Aug; 2 (8):722-35.
42. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J, Ren X. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013 Apr 1; 190(7):3783-97.
43. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P. The combined effects of tryptophan starvation andtryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006; 176:6752-61.
44. Baban B, Chandler PR, Sharma M, Pihkala J, Koni PA, Munn DH, Mellor AL. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 2009; 183:2475-83.
45. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, van der Burg SH, Fleuren GJ. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res. 2008 Apr 1;14(7):2028-35.
46. Fatokun AA, Hunt NH, Ball HJ. Indoleamine 2,3- dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease. Amino Acids 2013; 45:1319-29.
47. Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ, Prendergast GC. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D- 1-methyl-tryptophan. Oncoimmunol 2012; 1:1460-8.
48. Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Nei- lan C, Haley PJ, Burn T, Waeltz P, Sparks RB, Yue EW, Combs AP, Scherle P, Vaddi K, Fridman JS. Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing tumours. Mol Cancer Ther 2010; 9:489-98.
49. Dolusic E, Frederick R. Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008-2012). Expert Opin Ther Pat 2013; 23:1367-81.
50. de Jong WH, Smit R, Bakker SJ, et al. Plasma tryptophan, kynurenine and 3-hydroxykynurenine measurement using automated on-line solid-phase extraction HPLC-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877(7):603-9.